Cornerstone BioPharma Licenses Drug
Posted November 10, 2006
CARY, N.C. — Cornerstone BioPharma
has licensed an antibiotic drug for treatment of infections of the lungs, throat and skin from a Japanese pharmaceutical firm.
Financial terms were not disclosed.
Cornerstone, which focuses on respiratory drugs, acquired the rights to Spectracef from Meiji Seika Kaisha. The deal covers licensing rights in the U.S.
Spectracef is an oral antibiotic. It targets pneumonia, bronchitis, tonsillitis and various skin infections.